von Hippel-Lindau syndrome: Target for anti-vascular endothelial growth factor (VEGF) receptor therapy

Oncologist

Volumn 5, Issue SUPPL. 1, 2000, Pages 32-36

  Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; Hypoxia inducible factors; Vascular endothelial growth factor; Von Hippel Lindau Syndrome

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VON HIPPEL LINDAU DISEASE;

EID: 0033996775     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-suppl_1-32     Document Type: Conference Paper

References (45)

1. Friedrich CA. Von Hippel-Lindau syndrome: a pleomorphic condition. Cancer 1999;86:1658-1662.
2. Glenn GM, Choyke PL, Zbar B et al. Von Hippel-Lindau disease: clinical review and molecular genetics. Problems in Urology 1990;4:312-330.
3. Kaelin WG Jr, Maher ER. The VHL tumour-suppressor gene paradigm. Trends Genet 1998;14:423-426.
4. Ohh M, Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today 1999;5:257-263.
5. Maher ER, Yates JR, Harries R et al. Clinical features and natural history of von Hippel-Lindau disease. QJM 1990;77:1151-1163.
6. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
7. Chen F, Kishida T, Yao M et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
8. Gallou C, Joly D, Mejean A et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999;13:464-475.
9. Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 1998;243:541-545.
10. Bradley JF, Collins DL, Schimke RN et al. Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene. Am J Med Genet 1999;87:163-167.
11. van der Harst E, de Krijger RR, Dinjens WN et al. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 1998;77:337-340.
12. Webster AR, Richards FM, MacRonald FE et al. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet 1998;63:1025-1035.
13. Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999;117:371-378.
14. Choyke PL, Glenn GM, Walther MM et al. von Hippel-Lindau disease: genetic, clinical, and imaging features [published erratum appears in Radiology 1995;196:582]. Radiology 1995;194:629-642.
15. Hes FJ, Feldberg MA. Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses). Eur Radiol 1999;9:598-610.
16. Tyers M, Willems AR. One ring to rule a superfamily of E3 ubiquitin ligases. Science 1999;284:601-604.
17. Patton EE, Willems AR, Tyers M. Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. Trends Genet 1998;14:236-243.
18. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999;284:455-461.
19. Pause A, Peterson B, Schaffar G et al. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci USA 1999;96:9533-9538.
20. Liakopoulos D, Busgen T, Brychzy A et al. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc Natl Acad Sci USA 1999;96:5510-5515.
21. Lisztwan J, Imbert G, Wirbelauer C et al. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999;13:1822-1833.
22. Botuyan MV, Koth CM, Mer G et al. Binding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin C. Proc Natl Acad Sci USA 1999;96:9033-9038.
23. Ye Y, Vasavada S, Kuzmin I et al. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer 1998;78:62-69.
24. Lee S, Neumann M, Stearman R et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 1999;19:1486-1497.
25. Hemberger M, Himmelbauer H, Neumann HP et al. Expression of the von Hippel-Lindau-binding protein-1 (Vbp1) in fetal and adult mouse tissues. Hum Mol Genet 1999;8:229-236.
26. Kamura T, Koepp DM, Conrad MN et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-661.
27. Okuda H, Hirai S, Takaki Y et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 1999;263:491-497.
28. Schoenfeld A, Davidowitz EJ, Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1998;95:8817-8822.
29. Iliopoulos O, Ohh M, Kaelin WG Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998;95:11661-11666.
30. Blankenship C, Naglich JG, Whaley JM et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 1999;18:1529-1535.
31. Kamura T, Sato S, Haque D et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras. WD-40 repeat, and ankyrin repeat families. Genes Dev 1998;12:3872-3881.
32. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [letter]. Nature 1999;399:271-275.
33. Iliopoulos O, Levy AP, Jiang C et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595-10599.
34. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev 1998;17:187-194.
35. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-8109.
36. Wiesener MS, Turley H, Allen WE et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 alpha. Blood 1998;92:2260-2268.
37. Ananth S, Knebelmann B, Grüning W et al. Transforming growth factor betal is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999;59:2210-2216.
38. Koochekpour S. Jeffers M, Wang PH et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-5912.
39. Los M, Zeamari S, Foekens JA et al. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1999;59:4440-4445.
40. Ivanov SV, Kuzmin I, Wei MH et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95:12596-12601.
41. Ohh M, Yauch RL, Lonergan KM et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968.
42. Krieg M, Marti HH, Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998;92:3388-3393.
43. Brieger J, Weidl EJ, Schirmacher P et al. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors. J Mol Med 1999;77:505-510.
44. Flamme I, Krieg M, Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol 1998;153:25-29.
45. Wizigmann-Voos S, Breier G, Risau W et al. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995;55:1358-1364.